Ocrelizumab (Ocrevus) is the newest infusion treatment for MS. It was approved by the FDA in 2017. It’s the first drug used to treat primary progressive MS (PPMS). It’s also used to treat CIS ...

It is also the first drug approved for patients with primary progressive MS (PPMS), where symptoms get worse over time. In an interview with pharmaphorum, Marius Scholtz, country medical lead for ...

The exact cause of MS is unknown, but it is thought US, NY, UNITED STATES, January 31, 2025 /EINPresswire / -- Multiple Sclerosis Ms Drugs market ... (RRMS), Primary Progressive Multiple Sclerosis ...

Hired in 2019 as the ACLU’s first DEI chief, AJ Hikes has also emerged at the center of a labor-rights case against the nonprofit that deemed it ...

Medications are the mainstay of treatment for multiple ... Ocrelizumab is an infusion medication that treats CIS, relapsing-remitting MS, and primary progressive MS. It works similarly to ofatumumab, ...

During his first two years in office, Maryland State's Attorney Ivan Bates's team, which includes 185 prosecutors, took 2,129 ...

For most people, that urge is more intense when trying to sleep. MS medications cannot relieve PLMS or RLS. A sleep specialist, however, might be able to help treat it. Hypersomnia causes you to ...

It’s also approved for primary progressive MS (PPMS). Administered via an intravenous ... Ocrevus was approved by the U.S. Food and Drug Administration (FDA) in 2017 to treat adults with ...

Roche is running three late-stage studies, namely FENhance 1 and 2 trials in relapsing MS, comparing the drug to Sanofi's Aubagio (teriflunomide) and the FENtrepid trial in primary progressive MS ...

Many DMT drugs are also approved to treat clinically isolated ... Ocrevus Zunovo is approved for the treatment of primary progressive MS and relapsing forms of MS, including clinically isolated ...